GlassScriptPhysician profile
Nancy J Spicer
NPI 1598768574
$4,532.14
in general payments reported to CMS, 2019-2025
25 companies · $1,563 in 2025
The $1,563 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $615 · 2022: $308 · 2023: $751 · 2024: $1,295 · 2025: $1,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,608.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,117.77 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $648.56 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Madrigal Pharmaceuticals | $415.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Otsuka America Pharmaceutical, INC. | $231.15 | 2023-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $225.80 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $220.91 | 2022-2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $196.46 | 2022-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $189.50 | 2021-2023 | Xarelto |
| Glaxosmithkline, LLC. | $164.43 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.90 | 2023-2025 | Ofev, Jardiance, Synjardy |
| Verona Pharma, INC. | $140.86 | 2025 | Ohtuvayre |
| Amgen INC. | $127.72 | 2023-2025 | Otezla, Repatha, Evenity |
| Biohaven Pharmaceuticals, INC. | $119.27 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.60 | 2023-2025 | |
| Abbvie INC. | $93.18 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $66.85 | 2024-2025 | Gemtesa |
| Sun Pharmaceutical Industries INC. | $58.92 | 2021 | |
| Pfizer INC. | $48.75 | 2023-2025 | |
| Baxter Healthcare | $44.72 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Dexcom, INC. | $41.04 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $35.10 | 2025 | Rexulti |
| Shield Therapeutics INC | $27.69 | 2023-2024 | Accrufer |
| Merck Sharp & Dohme LLC | $22.11 | 2023 | Verquvo, Belsomra, Steglatro |
| Exact Sciences Corporation | $21.74 | 2025 | The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $15.37 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Spicer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.